Lytix Biopharma is selling at 7.20 as of the 25th of September 2025; that is 2.27 percent up since the beginning of the trading day. The stock's open price was 7.04. Lytix Biopharma has hardly any chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of June 2025 and ending today, the 25th of September 2025. Click here to learn more.
Although Lytix Biopharma's alpha and beta are two of the key measurements used to evaluate Lytix Biopharma's performance over the market, the standard measures of volatility play an important role as well.
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lytix Biopharma stock to make a market-neutral strategy. Peer analysis of Lytix Biopharma could also be used in its relative valuation, which is a method of valuing Lytix Biopharma by comparing valuation metrics with similar companies.